Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bright Minds Biosciences

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
From Bright Minds Biosciences
Via GlobeNewswire
Tickers AIFF CSE:DRUG DRUG
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
From Bright Minds Biosciences
Via GlobeNewswire
Tickers CSE:DRUG DRUG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.